Does Shilajit Reverse Osteoporosis and Osteopenia? What the Human Clinical Trial Actually Shows

The reason this one human trial matters so much is that it showed something else. The women taking purified shilajit gained bone density back at both the spine and the hip, while the placebo group continued the slide that menopause sets in motion.

That is the difference between renting a little time and actually turning the trend around. The rest of this article walks through exactly how the study was run, what it measured, and what it found, with the numbers kept in plain language.

The human study, in plain terms

The trial was published in 2022 in the peer reviewed journal Phytomedicine by Pingali and Nutalapati, run at Nizam's Institute of Medical Sciences in Hyderabad. It is the first clinical trial to show a dietary shilajit ingredient improving bone mineral density in people, not in a dish and not in animals.

Here is how it was built.

It ran for 48 weeks. It was randomized, double blind, and placebo controlled, which is the highest standard for this kind of research. Neither the women nor the researchers knew who was getting what until the end.

Sixty postmenopausal women took part, all aged 45 to 60 and all within five years of their last period. Every one of them already had low bone mass. Sixty eight were screened, sixty enrolled, and fifty nine finished.

They were split into three groups of about twenty. One group took a placebo. One took 250 mg a day of purified shilajit. One took 500 mg a day. The shilajit was a standardized, purified extract, set to at least 50 percent fulvic acid, taken once a day after food.

One detail matters for how seriously to take this. These were not mildly affected women. Their average spine T score was about minus 2, which is osteopenia. Their average hip T score was about minus 2.5, which crosses the line into osteoporosis. So this group was already losing bone and already at real risk of fracture.

What the researchers measured

The study did not rely on a single number. It tracked three different layers of what happens to aging bone, which is what makes the result believable.

First, bone mineral density itself, measured by DXA scan at the lumbar spine and the femoral neck (the hip) at the start, at 24 weeks, and at 48 weeks. This is the gold standard bone scan your own doctor uses.

Second, bone turnover markers in the blood, the chemical signals that show whether your body is in breakdown mode or build mode. These shift long before a scan can, so they are an early read on which way things are headed.

Third, the markers of inflammation and oxidative stress that rise after menopause and quietly accelerate bone loss in the background.

The result that matters most: bone density went up

Here is the headline, and it is the reason this study is worth reading.

The placebo group kept losing bone. Their density at both the spine and the hip dropped significantly over the 48 weeks. That is the normal, expected path after menopause when nothing changes the underlying signal.

Both shilajit groups went the other way. Bone density at the spine and the hip was preserved and increased from where each woman started, and the higher 500 mg dose did more than the 250 mg dose. Every single woman in the treatment group reversed her osteopenia within 24 weeks.

Sit with the contrast for a moment. Same age, same starting point, same 48 weeks. One group watched their bones get weaker. The other group watched them get stronger. The only difference on the table was the shilajit.

The reason it worked, read in the blood

Bone is alive. All day, every day, it is being broken down a little and built back a little. After menopause that balance tips toward breakdown, and the scan slowly falls. The blood markers in this study show the shilajit tipping it back.

CTX-1 is the marker of bone being torn down. In the placebo group it rose by about 11 percent over the study. In the 500 mg shilajit group it fell by about 22 percent. Less tearing down.

Then there are two signals that work as a pair, RANKL and OPG. RANKL is the message that tells your body to break bone down. OPG is the message that protects bone and shields it from that order. The ratio between them is one of the clearest pictures of which direction bone is moving.

On placebo, RANKL went up and OPG went down, exactly the wrong way. On 500 mg of shilajit, RANKL dropped while OPG rose by about 57 percent, and the whole RANKL to OPG ratio fell by about 42 percent. In plain terms, the body stopped being told to dismantle bone and started being told to protect and rebuild it.

That is the mechanism behind the scan. The density went up because the underlying instructions changed.

The quieter engine: inflammation and oxidative stress

There is a second layer to why bone fails after menopause, and the study measured it too.

When estrogen falls, low grade inflammation and oxidative stress rise. Think of oxidative stress as internal rust and inflammation as a slow background fire. Both of them speed up bone loss, and both of them climb in the years right after menopause.

The shilajit calmed both. hsCRP, a marker of inflammation, fell by about 30 percent in the higher dose group while it rose in the placebo group. MDA, a marker of oxidative damage, fell by about 20 percent. GSH, the body's master antioxidant, rose by about 37 percent. Nitric oxide, which keeps blood vessels healthy and tends to drop through menopause, rose by 50 to 60 percent.

So the shilajit was not only changing the bone signal. It was turning down the fire and the rust that were feeding the loss in the first place.

Why "reverse" is the right word, and how this differs from the usual route

The common bone loss medications are antiresorptive. That is a long word for one idea, they slow how fast you take bone apart. They are a brake. They are not a builder. On those, the best case is usually that you lose less.

This trial showed something the brake cannot do. Density rose from baseline. The body was not just losing more slowly, it was putting bone back. That is the distinction worth understanding before you decide what to do about your own numbers.

It is also worth naming what this is not. Shilajit is not a hormone, and it does not pour estrogen into you. After menopause the problem is that the estrogen signal that tells bone to keep rebuilding has gone quiet. Shilajit and the fulvic acid in it work on that signaling and on the breakdown to build ratio, supporting your body's own machinery rather than replacing a hormone. That is why it can sit alongside the rest of a woman's routine.

What the lab and animal research adds underneath

A single human trial is strongest when the why underneath it is consistent. Here the supporting research lines up, and we are careful to label what is a human result and what is earlier stage.

In a laboratory study, Kangari and colleagues in 2022 found that shilajit sped up the maturation of human stem cells into bone building cells, raising the markers of active bone formation. This is cell research, not a human outcome, but it points the same direction.

In cell culture, Abbasi and colleagues in 2019 found that a low dose of shilajit increased the growth of osteoblasts, the cells whose whole job is to make new bone.

In ovariectomized rats, a standard animal model of menopause, Alshubaily and colleagues in 2022 found that shilajit improved bone mineral density and lowered bone turnover markers, the same pattern later seen in the human trial.

None of those replace the human study. What they do is explain the engine. The cells build more bone, the breakdown signal comes down, and in the one place it counts, real postmenopausal women, the density went up.

Dose: more was better, within reason

The trial tested two doses, and the higher one did more. The 250 mg dose preserved and improved bone. The 500 mg dose did it more strongly across the density scans and the blood markers alike. This is what researchers call a dose dependent effect, and it is another sign the result is real rather than chance, because the response tracked the amount.

Safety, and the purity question women always ask

The safety read in this trial was clean. Vitamin D levels did not change in any group, which matters because it means the bone gains were not just the result of added vitamin D. Every blood safety lab stayed in the normal range. Not one woman dropped out because of a side effect.

That fits the broader record. Across every human clinical study ever done on shilajit, zero serious adverse events have been reported.

Purity is the fair question to ask about any mineral resin, so here is the honest answer for ours. Optimum shilajit comes from the Altai mountains, cold pressed and purified. Every batch is third party lab tested, heavy metal free, and Prop 65 compliant in California. We are a small, family owned company out of Florida, and a real person answers when you reach out. It comes as a box of tablets, not a loose powder that loses its fulvic acid before it ever reaches you.

What this actually means for you

Strip away the markers and the abbreviations and here is what the study describes. A group of women your age, already past menopause, already losing bone, took a purified shilajit every day. Within 24 weeks their osteopenia had reversed, and by the end their bone was measurably stronger than where they started, while the women who took nothing kept getting weaker.

That is the floor you stand on when you decide what to do next. Not a promise, a published human result, with the numbers in the open.

Optimum Shilajitwomen

If you want to give your own bones the signal they have been missing, you can find Optimum Shilajit for women.

See Optimum Shilajitwomen